(Total Views: 411)
Posted On: 08/20/2021 3:38:27 PM
Post# of 153767
Re: Evil Rabbit #100950
What's really bonkers is "spike targeting" MABs are only likely to be useful for a short while more.. spike changes (new variants) = lower binding affinity
Quote:
The US government is no longer distributing Eli Lilly's bamlanivimab into California, Arizona and Nevada because of the prevalence of a viral variant that is not susceptible to the monoclonal antibody, FDA acting commissioner Janet Woodcock told physicians taking part in a webinar with the American Medical Association ...Mar 17, 2021
(0)
(0)
